Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Chief Medical Officer | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tonix Pharmaceuticals Holding Corp.
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.29 · Expires 2036-02-24 | Direct | 39,012 |
Reported balance
After 2026-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-24 · Grant · Acquired 39,012 · Balance 39,012 F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.86 · Expires 2036-02-24 | Direct | 39,011 |
Reported balance
After 2026-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-24 · Grant · Acquired 39,011 · Balance 39,011 F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 26, 2026 07:02 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,011 | $0.00 Strike: $17.86 | $0.00 |
DisclosureSEC source: 0001999371-26-004387 · sullivan-form4_022626.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,011 Underlying: Common Stock · 39,011 shares Expires 2036-02-24 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 07:02 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,012 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0001999371-26-004387 · sullivan-form4_022626.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,012 Underlying: Common Stock · 39,012 shares Expires 2036-02-24 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 18:49 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 29,017 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001839882-25-011955 · sullivan_form4-022725.xml · derivative · entry 3 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,017 Underlying: Common Stock · 29,017 shares Expires 2035-02-25 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 18:49 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 29,017 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001839882-25-011955 · sullivan_form4-022725.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,017 Underlying: Common Stock · 29,017 shares Expires 2035-02-25 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 05, 2025 Filed Feb 27, 2025 18:49 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock, par value $0.001 | 0.11 | $1.47 | $0.16 |
DisclosureSEC source: 0001839882-25-011955 · sullivan_form4-022725.xml · nonDerivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Involuntary sale of fractional shares following a reverse stock split of the Issuer's common stock Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 17:05 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 358,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001999371-24-002949 · ownership.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,000 Underlying: Common Stock · 358,000 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 17:05 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 358,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001999371-24-002949 · ownership.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,000 Underlying: Common Stock · 358,000 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 18:38 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 220,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001839882-23-004704 · ownership.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2033-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 18:38 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 220,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001839882-23-004704 · ownership.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2033-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 17:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 1,250,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001387131-22-002108 · ownership.xml · derivative · entry 4 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 17:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 1,250,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001387131-22-002108 · ownership.xml · derivative · entry 3 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 17:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 1,250,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001387131-22-002108 · ownership.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 17:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 1,250,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001387131-22-002108 · ownership.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| June 30, 2021 Filed Feb 11, 2022 17:17 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, par value $0.001 | 36,496 | $0.58 | $21,167.68 |
DisclosureSEC source: 0001387131-22-001714 · ownership.xml · nonDerivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,223 F1 · date: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 17:47 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 750,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001387131-21-002884 · ownership.xml · derivative · entry 3 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2031-02-23 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 17:47 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 750,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001387131-21-002884 · ownership.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2031-02-23 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| January 07, 2021 Filed Feb 25, 2021 17:47 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, $0.001 par value | 41,322 | $0.51 | $21,074.22 |
DisclosureSEC source: 0001387131-21-002884 · ownership.xml · nonDerivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,727 F1 · timeliness: The shares were purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan and are not required to be filed on a Form 4. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 09:02 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, par value $0.001 | 20,000 | $1.03 | $20,600.00 |
DisclosureSEC source: 0001387131-20-007672 · ownership.xml · nonDerivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,405 Read SEC document |
| May 04, 2020 Filed May 6, 2020 18:24 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 500,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001387131-20-004483 · ownership.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-05-04 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| May 04, 2020 Filed May 6, 2020 18:24 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 500,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001387131-20-004483 · ownership.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-05-04 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 16:23 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001387131-20-002255 · ownership.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2030-02-25 F2 · price: The option was granted pursuant to the Issuer's 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 16:23 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001387131-20-002255 · ownership.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2030-02-25 F2 · price: The option was granted pursuant to the Issuer's 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| July 31, 2019 Filed Feb 14, 2020 16:15 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, par value $0.001 | 1,142 | $11.82 | $13,498.44 |
DisclosureSEC source: 0001387131-20-001794 · sullivan-form5_123119.xml · nonDerivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405 F2 · date: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2019 Employee Stock Purchase Plan. Read SEC document |
| May 06, 2019 Filed May 8, 2019 08:01 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 43,252 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001387131-19-003427 · ownership.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,252 Underlying: Common Stock · 43,252 shares Expires 2029-05-06 F2 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| May 06, 2019 Filed May 8, 2019 08:01 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 43,253 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001387131-19-003427 · ownership.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,253 Underlying: Common Stock · 43,253 shares Expires 2029-05-06 F2 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 17:33 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 7,755 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001387131-19-001530 · sullivan-form4_02262019.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,755 Underlying: Common Stock · 7,755 shares Expires 2029-02-25 F2 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 17:33 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 7,755 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001387131-19-001530 · sullivan-form4_02262019.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,755 Underlying: Common Stock · 7,755 shares Expires 2029-02-25 F2 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 17, 2019 Filed Feb 14, 2020 16:15 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, par value $0.001 | 59 | $17.85 | $1,053.15 |
DisclosureSEC source: 0001387131-20-001794 · sullivan-form5_123119.xml · nonDerivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405 F1 · date: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2018 Employee Stock Purchase Plan. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 07:05 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 10,000 | $3.97 | $39,650.00 |
DisclosureSEC source: 0001615774-18-005327 · s110851_form4.xml · nonDerivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,482 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 16:09 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 58,725 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001615774-18-001264 · s109081_form4.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,725 Underlying: Common Stock · 58,725 shares Expires 2028-02-12 F2 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 16:09 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 58,726 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001615774-18-001264 · s109081_form4.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,726 Underlying: Common Stock · 58,726 shares Expires 2028-02-12 F2 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 21:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001615774-17-000856 · s105457_form4.xml · derivative · entry 2 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-01 F2 · price: The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan. F3 · derivative.exercise_date: The option vests 50% if the Issuer achieves enrollment of 250 patients in its HONOR study by December 31, 2017, with the remaining 50% vesting 1% for each patient that is enrolled in the HONOR study by December 31, 2017 in excess of 250, subject to a one year minimum service period prior to vesting. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 21:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001615774-17-000856 · s105457_form4.xml · derivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-01 F2 · price: The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| June 30, 2016 Filed Feb 13, 2017 09:52 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock | 3,296 | $1.74 | $5,735.04 |
DisclosureSEC source: 0001615774-17-000521 · s105312_form5.xml · nonDerivative · entry 1 SULLIVAN GREGORY M · CIK 0001610106 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,481 F1 · kind: Shares acquired through the Tonix Pharmaceuticals Holding Corp. Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.